Episode 10 of the “Dialogues in CDx” podcast series focuses on the practical aspects of biomarker testing in ovarian cancer and its growing role in treatment decision-making. The discussion explores testing workflows, reflex versus on-demand testing, tissue selection, re-biopsy considerations, and assay validation. The speakers highlight the importance of collaboration between oncologists and pathologists, discuss current challenges in biomarker interpretation, and look ahead to emerging biomarkers and future innovations in precision oncology. Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, and biomarker-driven patient care. Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and is widely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies. This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent’s CDx Digital Education Portal today: https://bit.ly/3EETZ9t The “Dialogues in CDx” podcast can also be found on Spotify and on Apple Podcasts. D0151977_1.00

 119      1